

Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Dexamethasone Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 50 Tuas West Drive

Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	
Starch	9005-25-8	>= 30 -< 50	
Dexamethasone	50-02-2	>= 0.25 -< 0.3	

4. FIRST AID MEASURES



Dexamethasone Solid Formulation

Version SDS Number: Date of last issue: 04.04.2023 Revision Date: 2.1 30.09.2023 2533181-00013 Date of first issue: 23.02.2018

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delaved

Protection of first-aiders

Contact with dust can cause mechanical irritation or drying of the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection. and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents



Dexamethasone Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.1 30.09.2023 2533181-00013 Date of first issue: 23.02.2018

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Starch	9005-25-8	PEL (long term)	10 mg/m3	SG OEL	
		TWA	10 mg/m3	ACGIH	
Dexamethasone	50-02-2	TWA	10 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	100 μg/100 cm ²	Internal	

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type
Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment,



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

products

Oxidizing agents

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation Skin contact

> Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Dexamethasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 6,500 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): 14 mg/kg

Application Route: Subcutaneous



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Skin corrosion/irritation

Not classified based on available information.

Components:

Dexamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species : Rabbit

Result : No eye irritation

Dexamethasone:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Dexamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Test Type: in vitro assay

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Dexamethasone:

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 6 mg/kg body weight Result: Specific developmental abnormalities, Cleft palate

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: NOAEL: 0.025 mg/kg body weight

Result: Specific developmental abnormalities

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: >= 0.062 mg/kg body weight

Result: Specific developmental abnormalities

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: >= 0.02 mg/kg body weight

Result: Skeletal and visceral variations, Retardations

Reproductive toxicity - As-

sessment

May damage the unborn child.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Dexamethasone:

Exposure routes : Oral



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Target Organs : Adrenal gland, Immune system, thymus gland

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Dexamethasone:

Species : Rat

NOAEL : 0.0015 mg/kg

Application Route : Oral Exposure time : 7 d Target Organs : Liver

Remarks : Significant toxicity observed in testing

Species : Rat

LOAEL : 0.003 mg/kg

Application Route : Oral Exposure time : 90 d

Target Organs : Blood, Adrenal gland, thymus gland Remarks : Significant toxicity observed in testing

Species : Rat

LOAEL : 0.125 mg/kg
Application Route : Oral
Exposure time : 6 Weeks
Target Organs : Adrenal gland

Remarks : Significant toxicity observed in testing

Species : Rat
LOAEL : 0.4 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system

Remarks : Significant toxicity observed in testing

Species : Dog
LOAEL : 8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Immune system

Remarks : Significant toxicity observed in testing



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Dexamethasone:

Ingestion : Target Organs: Immune system

Target Organs: Adrenal gland

Target Organs: Bone

Symptoms: muscle weakness

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Dexamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 56 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.033 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

M-Factor (Chronic aquatic

toxicity)

: 1

Toxicity to microorganisms

EC50: > 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Persistence and degradability

Components:

Dexamethasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 3.54 d

Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Dexamethasone:

Partition coefficient: n-

octanol/water

log Pow: 1.83

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Packing instruction (cargo :

Not applicable

aircraft)

Packing instruction (passen-

Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Not applicable Proper shipping name Not applicable Class Not applicable Subsidiary risk Not applicable Packing group Labels Not applicable **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazard-

: Not applicable

ous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials)

Regulations

: Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 30.09.2023

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

SG OEL : Singapore. Workplace Safety and Health (General Provisions)

Regulations - First Schedule Permissible Exposure Limits of

Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average

SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals: ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.



Dexamethasone Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 2533181-00013
 Date of first issue: 23.02.2018

SG / EN